Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase - 17/05/23
Doi : 10.1016/j.jinf.2023.02.029
Eric Yuk Fai Wan
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China
Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Boyuan Wang, Sukriti Mathur, Cheyenne I. Ying Chan
Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Vincent Ka Chun Yan
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Francisco Tsz Tsun Lai
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China
Celine Sze Ling Chui
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China
School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Xue Li
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China
Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Carlos King Ho Wong
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China
Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Philip Hei Li, Chak Sing Lau
Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Ian Chi Kei Wong 
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China
Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
Aston Pharmacy School, Aston University, Birmingham B4 7ET, UK
Esther Wai Yin Chan ⁎
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China
Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China
∗Correspondence to: Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-56 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, China.Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong KongL02-56 2/F, Laboratory Block, 21 Sassoon RoadPokfulamHong Kong, China
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
Plan
| ☆ | Eric Yuk Fai Wan, Boyuan Wang, and Sukriti Mathur are co-first authors and contributed equally. |
© 2023
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 86 - N° 6
P. 622-625 - juin 2023 Retour au numéro
Article précédent
- Allopurinol increased the risk of COVID-19 hospitalization mediated by E-Selectin downregulation
- Kai Zhang, Rukun Chen, Qixia Jiang
- Infection dynamics of Stenotrophomonas maltophilia in patients with cystic fibrosis
- Beverley C. Millar, John McCaughan, Jacqueline C. Rendall, John E. Moore
Bienvenue sur EM-consulte, la référence des professionnels de santé.